Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Oct 10;25(1):734.
doi: 10.1186/s12872-025-05133-5.

Efficacy and safety of continuation vs. interruption of anticoagulation during transcatheter aortic valve implantation: A systematic review and meta-analysis

Umar G Adamu  1 , Marheb Badianyama  2 , Anupa Patel  2 , Arthur Mutyaba  2 , Nqoba Tsabedze  2
Affiliations
Meta-Analysis

Efficacy and safety of continuation vs. interruption of anticoagulation during transcatheter aortic valve implantation: A systematic review and meta-analysis

Umar G Adamu et al. BMC Cardiovasc Disord. .

Abstract

Background: The appropriate periprocedural management of oral anticoagulation in transcatheter aortic valve implantation (TAVI) patients who require long-term anticoagulation remains controversial.

Purpose: This systematic review and meta-analysis compare the efficacy and safety of periprocedural continuation versus interruption of anticoagulation in patients undergoing TAVI with an indication for long-term anticoagulation.

Methods: We searched PubMed, Embase, and Cochrane Central databases to identify relevant articles. We included both observational and randomized controlled trials. Data were analysed using random-effects model to calculate the odds ratio (OR) with 95% confidence intervals (CIs). A p < .05 was considered statistically significant.

Results: Four studies comprising 3,144 patients, with anticoagulation continued in 1,500 (47.7%) patients were included. There were no difference between periprocedural continuation and interruption of anticoagulation in the incidence of composite outcomes (OR: 0.84; 95% CI: 0.64-1.10; p = .19), major bleeding (OR: 0.98; 95% CI: 0.57-1.68; p = .95), major vascular complications (OR: 0.93; 95% CI: 0.72-1.20; p = .60), and myocardial infarction (MI) (OR: 0.60; 95% CI: 0.20-1.77; p = .36). However, the incidence of stroke was significantly lower in the continuation group (OR: 0.61; 95% CI: 0.39-0.94; p = .03). The incidence of blood transfusion was not significantly different between the continuation and interruption groups (OR: 0.86; 95% CI: 0.42-1.77; p = .68).

Conclusions: In this meta-analysis comparing periprocedural continuation of anticoagulation to interruption of therapy in patients undergoing TAVI with concomitant indications for long-term anticoagulation, continuation of anticoagulation was associated with a lower incidence of stroke without increasing the risk of bleeding. These findings suggest a potentially favourable safety profile in favour of continuation of anticoagulant therapy, they should be interpreted with caution and validated in larger and well-designed randomised trials. The review protocol was prospectively registered with the International Prospective Register of Systematic Reviews (PROSPERO), registration number (CRD42024607149).

Keywords: Anticoagulation; Continuation; Interruption; Meta-analysis; Periprocedural; Transcatheter aortic valve implantation.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram of study screening and selection
Fig. 2
Fig. 2
Efficacy and safety of continuation vs. interruption of anticoagulation during transcatheter Aortic Valve Implantation. A Composite primary outcome, (B) Major vascular bleeding, (C) Closure device failure, (D) Cardiovascular mortality, (E) Stroke, and (F) Blood transfusion. CI: confidence interval, MH: Mantel-Haenszel
See this image and copyright information in PMC

References

    1. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561–632. 10.1093/eurheartj/ehab395. - PubMed
    1. van Nieuwkerk AC, Aarts HM, Hemelrijk KI, Cantón T, Tchétché D, de Brito FS Jr, et al. Bleeding in patients undergoing transfemoral transcatheter aortic valve replacement: incidence, trends, clinical outcomes, and predictors. JACC Cardiovasc Interv. 2023;16(24):2951–62. 10.1016/j.jcin.2023.10.011. - PubMed
    1. Tarantini G, Mojoli M, Urena M, Vahanian A. Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome. Eur Heart J. 2017;38(17):1285–93. 10.1093/eurheartj/ehw456. - PubMed
    1. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366(18):1686–95. 10.1056/NEJMoa1200384. - PubMed
    1. Douketis JD, Spyropoulos AC, Murad MH, Arcelus JI, Dager WE, Dunn AS, et al. Perioperative management of antithrombotic therapy: an American college of chest physicians clinical practice guideline. Chest. 2022;162(5):e207–43. 10.1016/j.chest.2022.07.025. - PubMed

MeSH terms

LinkOut - more resources